| Name | Galectin-3 | ||
| UniProt ID | LEG3_HUMAN | ||
| Gene Name | LGALS3 | ||
| Gene ID | 3958 | ||
| Synonyms |
LGALS3, CBP35, GAL3, GALBP, GALIG, L31, LGALS2, MAC2
|
||
| Sequence |
MADNFSLHDALSGSGNPNPQGWPGAWGNQPAGAGGYPGASYPGAYPGQAPPGAYPGQAPP
GAYPGAPGAYPGAPAPGVYPGPPSGPGAYPSSGQPSATGAYPATGPYGAPAGPLIVPYNL PLPGGVVPRMLITILGTVKPNANRIALDFQRGNDVAFHFNPRFNENNRRVIVCNTKLDNN WGREERQSVFPFESGKPFKIQVLVEPDHFKVAVNDAHLLQYNHRVKKLNEISKLGISGDI DLTSASYTMI |
||
| Pathway Map | MAP LINK | ||
| T.C. Number | 9.B.9.1.14 | ||
| KEGG ID | hsa3958 | ||
| TTD ID | T72038 | ||
| Pfam | PF00337 | ||
| Pair Name | Rosmarinic acid, Anti-MUC1 antibody | |||
| Phytochemical | Rosmarinic acid | |||
| Drug | Anti-MUC1 antibody | |||
| Disease Info | [ICD-11: 2B72.Z] | Gastric cancer | Investigative | |
| Regulate Info | Down-regulation | Galectin-3 | Expression | |
| Result | Results of the study indicate that combined action of anti-MUC1 and RA is more effective than monotherapy in relation to examined cancer related factors. Such treatment can be considered as new, promising strategy in gastric cancer therapy. | |||
